Homology Medicines 将来の成長

Future 基準チェック /16

Homology Medicinesは、27.8%と13.2%でそれぞれ年率27.8%で利益と収益が成長すると予測される一方、EPSはgrowで27.8%年率。

主要情報

27.8%

収益成長率

27.8%

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	13.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	16 Nov 2023

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:35H - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2	-37	N/A	N/A	1
12/31/2025	2	-40	N/A	N/A	1
12/31/2024	1	-42	N/A	N/A	2
12/31/2023	1	-113	-96	-96	N/A
9/30/2023	2	-131	-102	-102	N/A
6/30/2023	3	-132	-102	-102	N/A
3/31/2023	3	-126	-109	-109	N/A
12/31/2022	3	-5	-115	-114	N/A
9/30/2022	3	-4	-119	-117	N/A
6/30/2022	4	-1	-119	-117	N/A
3/31/2022	5	-3	-113	-111	N/A
12/31/2021	34	-96	-112	-110	N/A
9/30/2021	34	-92	-94	-91	N/A
6/30/2021	33	-90	-97	-94	N/A
3/31/2021	31	-94	-101	-98	N/A
12/31/2020	3	-129	-98	-94	N/A
9/30/2020	2	-123	-116	-109	N/A
6/30/2020	2	-124	-114	-106	N/A
3/31/2020	2	-115	-113	-99	N/A
12/31/2019	2	-104	-113	-91	N/A
9/30/2019	2	-99	-107	-73	N/A
6/30/2019	3	-83	-98	-61	N/A
3/31/2019	4	-69	-84	-49	N/A
12/31/2018	5	-56	-68	-43	N/A
9/30/2018	4	-49	-22	-12	N/A
6/30/2018	3	-41	-9	-4	N/A
3/31/2018	1	-35	-2	0	N/A
12/31/2017	N/A	-30	5	6	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 35H今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 35H今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 35H今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 35Hの収益 ( 13.2% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 35Hの収益 ( 13.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 35Hの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Homology Medicines 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2022

Recent updates

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index

Full year 2023 earnings released: US$1.95 loss per share (vs US$0.087 loss in FY 2022)

Insufficient new directors

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Q32 Bio Inc. entered into a definitive merger agreement to acquire Homology Medicines, Inc. (NasdaqGS:FIXX) for approximately $200 million in a reverse merger transaction.

Third quarter 2023 earnings released: US$0.57 loss per share (vs US$0.59 loss in 3Q 2022)

Homology Medicines, Inc. Approves Reduction in Workforce

New major risk - Share price stability

New major risk - Revenue and earnings growth

Homology Medicines Announces First Data from IND-Enabling Studies with GTx-Mab Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, At the ASGCT Annual Meeting

First quarter 2023 earnings released: US$0.50 loss per share (vs US$1.61 profit in 1Q 2022)

Full year 2022 earnings released: US$0.087 loss per share (vs US$1.73 loss in FY 2021)

No longer forecast to breakeven

Homology Medicines, Inc. Provides Update on pheEDIT and juMPStart Clinical Trials

No longer forecast to breakeven

Third quarter 2022 earnings released: US$0.59 loss per share (vs US$0.54 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.59 loss per share (vs US$0.54 loss in 3Q 2021)

Insufficient new directors

Homology Medicines, Inc. Appoints Albert Seymour as Chief Executive Officer

Forecast to breakeven in 2022

Homology Medicines Announces Optimized, in Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy

Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2000 Dynamic Index

Homology Medicines, Inc. Announces FDA Lifted Clinical Hold on Phenix Gene Therapy Trial for Pku

First quarter 2022 earnings released: EPS: US$1.61 (vs US$0.021 loss in 1Q 2021)

Robbins Geller Rudman & Dowd LLP Announces That Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Homology Medicines, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Homology Medicines, Inc. Announces Promotion of Albert Seymour to President

Homology Medicines, Inc. Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU

Homology Medicines Announces Multiple Presentations on HMI-203 Gene Therapy Candidate for the Treatment of Hunter Syndrome

Insufficient new directors

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.62 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.54 loss per share (vs US$0.78 loss in 2Q 2020)

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from Russell 2500 Growth Index

Homology Medicines, Inc. Announces Presentations on Its Expanding Genetic Medicines Platform and Internal GMP Manufacturing

First quarter 2021 earnings released: US$0.021 loss per share (vs US$0.78 loss in 1Q 2020)

Full year 2020 earnings released: US$2.80 loss per share (vs US$2.47 loss in FY 2019)

Revenue misses expectations

Novartis Elects to Terminate the Collaboration and License Agreement with Homology Medicines, Inc

New 90-day high: €12.09

New 90-day high: €10.86

Homology Medicines, Inc. Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (Pku) and Hunter Syndrome (Mps Ii)

New 90-day low: €7.86

New 90-day low: €8.14

Third quarter 2020 earnings released: US$0.62 loss per share

Revenue beats expectations

Homology Medicines, Inc. announced that it expects to receive $60 million in funding from Pfizer Inc.

Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU

Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from S&P Biotechnology Select Industry Index

New 90-day low - €8.36

New 90-day low - €8.97

First half earnings released

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘